Occurrence of SARS-CoV-2 reinfections at regular intervals in Ecuador
- PMID: 36164552
- PMCID: PMC9507970
- DOI: 10.3389/fcimb.2022.951383
Occurrence of SARS-CoV-2 reinfections at regular intervals in Ecuador
Abstract
SARS-CoV-2 reinfection is defined as a new infection with a different virus variant in an individual who has already recovered from a previous episode of COVID-19. The first case of reinfection in the world was described in August 2020, since then, reinfections have increased over time and their incidence has fluctuated with specific SARS-CoV-2 variant waves. Initially, reinfections were estimated to represent less than 1% of total COVID-19 infections. With the advent of the Omicron variant, reinfections became more frequent, representing up to 10% of cases (based on data from developed countries). The frequency of reinfections in Latin America has been scarcely reported. The current study shows that in Ecuador, the frequency of reinfections has increased 10-fold following the introduction of Omicron, after 22 months of surveillance in a single center of COVID-19 diagnostics. Suspected reinfections were identified retrospectively from a database of RT-qPCR-positive patients. Cases were confirmed by sequencing viral genomes from the first and second infections using the ONT MinION platform. Monthly surveillance showed that the main incidence peaks of reinfections were reached within four to five months, coinciding with the increase of COVID-19 cases in the country, suggesting that the emergence of reinfections is related to higher exposure to the virus during outbreaks. This study performed the longest monitoring of SARS-CoV-2 reinfections, showing an occurrence at regular intervals of 4-5 months and confirming a greater propensity of Omicron to cause reinfections.
Keywords: COVID-19; SARS-CoV-2; genomic epidemiology; reinfection; sequencing.
Copyright © 2022 Guevara, Prado-Vivar, Márquez, Muñoz, Carvajal, Guadalupe, Becerra-Wong, Proaño, Bayas-Rea, Coloma, Grunauer, Trueba, Rojas-Silva, Barragán and Cárdenas.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
SARS-CoV-2 reinfections during the Delta and Omicron waves.JCI Insight. 2022 Oct 24;7(20):e162007. doi: 10.1172/jci.insight.162007. JCI Insight. 2022. PMID: 36048527 Free PMC article.
-
SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.Viruses. 2023 Jul 14;15(7):1551. doi: 10.3390/v15071551. Viruses. 2023. PMID: 37515237 Free PMC article.
-
Incidence, Risk, and Severity of SARS-CoV-2 Reinfections in Children and Adolescents Between March 2020 and July 2022 in Serbia.JAMA Netw Open. 2023 Feb 1;6(2):e2255779. doi: 10.1001/jamanetworkopen.2022.55779. JAMA Netw Open. 2023. PMID: 36780157 Free PMC article.
-
Incidence, severity, risk factors and outcomes of SARS-CoV-2 reinfections during the Omicron period: a systematic review and meta-analysis.J Glob Health. 2025 Feb 7;15:04032. doi: 10.7189/jogh.15.04032. J Glob Health. 2025. PMID: 39916552 Free PMC article.
-
Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.BMC Infect Dis. 2023 Jun 26;23(1):432. doi: 10.1186/s12879-023-08328-3. BMC Infect Dis. 2023. PMID: 37365490 Free PMC article.
Cited by
-
Single nucleotide variants in the CCL2, OAS1 and DPP9 genes and their association with the severity of COVID-19 in an Ecuadorian population.Front Cell Infect Microbiol. 2024 Apr 17;14:1322882. doi: 10.3389/fcimb.2024.1322882. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38694517 Free PMC article.
-
Assessment of the COVID-19 pandemic progression in Ecuador through seroprevalence analysis of anti-SARS-CoV-2 IgG/IgM antibodies in blood donors.Front Cell Infect Microbiol. 2024 Jun 21;14:1373450. doi: 10.3389/fcimb.2024.1373450. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38975325 Free PMC article.
References
-
- Abu-Raddad L. J., Chemaitelly H., Coyle P., Malek J. A., Ahmed A. A., Mohamoud Y. A., et al. . (2021). SARS-CoV-2 SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine 35:100861. doi: 10.1016/j.eclinm.2021.100861 - DOI - PMC - PubMed
-
- Bakker B. (2021) COVID-19 in Latin America a high toll on lives and livelihoods. Available at: http://elibrary.imf.org/view/journals/001/2021/168/001.2021.issue-168-en... (Accessed June 22, 2022).
-
- Barber R. M., Sorensen R. J. D., Pigott D. M., Bisignano C., Carter A., Amlag J. O., et al. . (2022). Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet 399, 2351–2380. doi: 10.1016/S0140-6736(22)00484-6 - DOI - PMC - PubMed
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous